Normobaric Hyperoxia Combined With Endovascular Treatment in Acute Ischemic Stroke (OPENS-2)
A Randomized Controlled Trial Assessing the Efficacy and Safety of Normobaric Hyperoxia for Acute Ischemic Stroke Patients Undergoing Endovascular Treatment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Xunming Ji, MD
- Phone Number: 01083199439
- Email: jixunming@vip.163.com
Study Contact Backup
- Name: Weili Li, PhD
- Email: liweilibeijing2008@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100069
- Xuan Wu Hospital,Capital Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
General inclusion criteria
- It conforms to the indications for endovascular thrombectomy
- 18 ≦ Age ≦ 80 years old.
- The clinical symptoms and signs are consistent with acute anterior circulation large vessel occlusion; 10≤NIHSS≤20;
- (Level of consciousness) NIHSS score 0 or 1;
- The time from onset to randomization is within 6 hours of onset;
- The mRS score before stroke is 0-1;
- Patient and family members sign informed consent. Image inclusion criteria
1. Preoperative CT or MR or DSA angiography found large vessel occlusion (internal carotid artery or middle cerebral artery M1 segment) that were consistent with symptoms and signs; 2. ASPECT score ≥ 6 points 3. <1/3 MCA area involvement (confirmed by CT or MRI)
Exclusion Criteria:
General exclusion criteria
- Rapid neurological function improvement, NIHSS score less than 10 points, or evidence of vessel recanalization prior to randomization;
- Seizures at stroke onset;
- Intracranial hemorrhage;
- Symptoms suggestive of subarachnoid hemorrhage, even if CT scan was normal;
- Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant therapy with INR > 3.0 or PTT > 3 times normal;
- Platelet count of less than 100,000 per cubic millimeter;
- Severe hepatic or renal dysfunction;
- Severe, sustained hypertension (Systolic Blood Pressure >185 mmHg or Diastolic Blood Pressure >110 mmHg)
- Baseline blood glucose of <50mg/dL (2.78 mmol) or >400mg/dL (22.20 mmol)
- Active and chronic obstructive pulmonary disease or acute respiratory distress syndrome;
- >3 L/min oxygen required to maintain peripheral arterial oxygen saturation (SaO2) 95% as per current stroke management guidelines;
- Medically unstable;
- Life expectancy<90 days;
- Patients who could not complete the 90-day follow-up;
- Evidence of intracranial tumor;
- Patients with anemia or polycythemia vera or other situations that require urgent oxygen inhalation;
- Patients with upper gastrointestinal bleeding or nausea or vomiting so that they cannot cooperate with the mask to inhale oxygen.
- A history of severe allergies to contrast agents;
- There are any other conditions that are not suitable for endovascular treatment.
Image exclusion criteria
- CTA/MRAshows excessive bending of blood vessels, which may hinder the delivery of the device;
- Suspected cerebrovascular inflammation based on medical history and CTA/MRA;
- Suspected aortic dissection based on medical history and CTA/MRA
- CTA/MRA confirmed multi-vascular area occlusion (such as bilateral anterior circulation or anterior/posterior circulation), or bilateral infarction or multi- regional infarction;
- CTA/MRAconfirmed moyamoya disease or moyamoya syndrome;
- CT/MRI confirmed the obvious effect of midline shift
- CT/MRI confirmed the presence of intracranial tumors
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NBO group
Normobaric Hyperoxia combined with endovascular mechanical thrombectomy
|
Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours.
If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
Other Names:
EVT is the international guidelines for the treatment of acute ischemic stroke with lage vessel occlusion.
Other Names:
|
|
Placebo Comparator: Control group
Inhale air placebo plus endovascular mechanical thrombectomy
|
EVT is the international guidelines for the treatment of acute ischemic stroke with lage vessel occlusion.
Other Names:
For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours.
If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%;
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modified Rankin Scale (mRS) score
Time Frame: 90 ± 14 days after randomization
|
the mRs is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability, and 6=death)
|
90 ± 14 days after randomization
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cerebral infarct volume
Time Frame: 24-48h after randomization
|
The infarct volume of cerebral infarct is evaluated by MRI or CT
|
24-48h after randomization
|
|
The proportion of good prognosis
Time Frame: 90 ± 14 days after randomization
|
defined by mRS 0-2
|
90 ± 14 days after randomization
|
|
The proportion of functional independence
Time Frame: 90 ± 14 days after randomization
|
defined by mRS 0-1
|
90 ± 14 days after randomization
|
|
The proportion of severe disability
Time Frame: 90 ± 14 days after randomization
|
defined by mRS 4-6
|
90 ± 14 days after randomization
|
|
Scores assessed by National Institutes of Health Stroke Scale(NIHSS)
Time Frame: 24 ± 6 hours, 72 ± 24 hours, 7 ± 2 days after randomization
|
Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits
|
24 ± 6 hours, 72 ± 24 hours, 7 ± 2 days after randomization
|
|
The proportion of neurological function improvement
Time Frame: 24 ± 6 hours after randomization
|
≥ 4 point reduction in NIHSS score from baseline
|
24 ± 6 hours after randomization
|
|
Successful vessel recanalization
Time Frame: Immediately after procedure
|
Successful vessel recanalization is defined by eTICI 2b/2c/3 on final angiogram.
Extended treatment in cerebral ischaemia (eTICI) score range from 0 to 3, with higher scores indicating better reperfusion
|
Immediately after procedure
|
|
Vessel recanalization
Time Frame: 24 ± 6 hours after randomization
|
Vessel recanalization is evaluated by CTA or MRA and assessed by AOL grades.
Arterial Occlusive Lesion (AOL) range from 0 to 3, with higher scores indicating better recanalization
|
24 ± 6 hours after randomization
|
|
Arterial oxygen partial pressure
Time Frame: after 4 hours of oxygen therapy
|
Laboratory indicators, obtained by arterial blood gas analysis
|
after 4 hours of oxygen therapy
|
|
Barthel Index (BI)
Time Frame: 90 ± 14 days after randomization
|
the BI is an ordinal disability score of 10 categories (range from 0 to 100, higher values indicate better prognosis)
|
90 ± 14 days after randomization
|
|
EuroQol five dimensions questionnaire(EQ-5D)
Time Frame: 90 ± 14 days after randomization
|
The score ranges from 0 to 100, with higher scores indicating optimal health
|
90 ± 14 days after randomization
|
|
Days of hospitalization
Time Frame: 90 ± 14 days after randomization
|
Length of stay in hospital
|
90 ± 14 days after randomization
|
|
All-cause mortality
Time Frame: 90 ± 14 days after randomization
|
Safety endpoint; the proportion of all patients who died in each group
|
90 ± 14 days after randomization
|
|
Serious adverse events
Time Frame: 90 ± 14 days after randomization
|
Safety endpoint; the proportion of serious adverse events in each group
|
90 ± 14 days after randomization
|
|
Stroke-related mortality
Time Frame: 90 ± 14 days after randomization
|
Safety endpoint; the proportion of stroke related deaths in each group
|
90 ± 14 days after randomization
|
|
Oxygen-related adverse events
Time Frame: 90 ± 14 days after randomization
|
Safety endpoint; the proportion of oxygen-related adverse events in each group, including severe lung infection, pneumothorax, atelectasis, respiratory failure, acute respiratory distress syndrome, and cardiopulmonary arrest
|
90 ± 14 days after randomization
|
|
Adverse events of special interest
Time Frame: 90 ± 14 days after randomization
|
Safety endpoint; the proportion of adverse events of special interest in each group, including malignant brain edema, perioperative myocardial infarction, and acute heart failure
|
90 ± 14 days after randomization
|
|
Symptomatic intracranial hemorrhage
Time Frame: 24 ± 6 hours after randomization
|
Safety endpoint; according to ECASS II definition
|
24 ± 6 hours after randomization
|
|
Any intracranial hemorrhage
Time Frame: 24 ± 6 hours after randomization
|
Safety endpoint; the proportion of any intracranial hemorrhage in each group
|
24 ± 6 hours after randomization
|
|
Early neurological deterioration (END)
Time Frame: 24 ± 6 hours after randomization
|
Safety endpoint; defined as ≥4 point increase in NIHSS score from baseline
|
24 ± 6 hours after randomization
|
|
Systolic and diastolic blood pressure
Time Frame: 24 ± 6 hours after randomization
|
Safety endpoint; vital signs
|
24 ± 6 hours after randomization
|
|
Heart rate
Time Frame: 24 ± 6 hours after randomization
|
Safety endpoint; vital signs
|
24 ± 6 hours after randomization
|
|
Respiratory rate
Time Frame: 24 ± 6 hours after randomization
|
Safety endpoint; vital signs
|
24 ± 6 hours after randomization
|
|
Oxygen saturation
Time Frame: 24 ± 6 hours after randomization
|
Safety endpoint; vital signs
|
24 ± 6 hours after randomization
|
|
PH of arterial blood gas analysis
Time Frame: after 4 hours of oxygen therapy
|
Safety endpoint
|
after 4 hours of oxygen therapy
|
|
PaCO2 of arterial blood gas analysis
Time Frame: after 4 hours of oxygen therapy
|
Safety endpoint
|
after 4 hours of oxygen therapy
|
|
Lactic acid of arterial blood gas analysis
Time Frame: after 4 hours of oxygen therapy
|
Safety endpoint
|
after 4 hours of oxygen therapy
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Xunming Ji, MD,PhD, Capital Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OPENS-2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.